Apellis Pharmaceuticals Inc (APLS.OQ)
APLS.OQ on NASDAQ Stock Exchange Global Select Market
13.84USD
15 Feb 2019
13.84USD
15 Feb 2019
Change (% chg)
$-0.37 (-2.60%)
$-0.37 (-2.60%)
Prev Close
$14.21
$14.21
Open
$14.35
$14.35
Day's High
$14.44
$14.44
Day's Low
$13.63
$13.63
Volume
98,697
98,697
Avg. Vol
111,533
111,533
52-wk High
$31.69
$31.69
52-wk Low
$11.45
$11.45
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Sep '18 | 0.00 | -0.640 |
| Jun '18 | 0.00 | -0.609 | |
| Mar '18 | 0.00 | -0.432 | |
| FY 2017 | Dec '17 | 0.00 | -0.371 |
| Sep '17 | 0.00 | -0.235 | |
| Jun '17 | 0.00 | -0.246 | |
| Mar '17 | 0.00 | -0.184 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 2 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Jun-19 | 2 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-19 | 2 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | 4 | -0.73 | -0.70 | -0.77 | -- |
| Quarter Ending Jun-19 | 4 | -0.74 | -0.68 | -0.77 | -- |
| Year Ending Dec-19 | 5 | -2.91 | -2.25 | -3.24 | -1.18 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 30.48 | 33.70 | |
| P/E High - Last 5 Yrs. | -- | 44.98 | 49.87 | |
| P/E Low - Last 5 Yrs. | -- | 23.63 | 24.25 | |
| Beta | -- | 0.90 | 0.90 | |
| Price to Sales (TTM) | -- | 4.12 | 6.29 | |
| Price to Book (MRQ) | -- | 5.10 | 5.26 | |
| Price to Tangible Book (MRQ) | -- | 5.85 | 6.77 | |
| Price to Cash Flow (TTM) | -- | 24.01 | 24.98 | |
| % Owned Institutions | -- | 0.90 | 1.69 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.49 | 1.40 | |
| Dividend Yield - 5 Year Avg | -- | 1.51 | 1.42 | |
| Dividend 5 Year Growth Rate | -- | 4.15 | 4.85 | |
| Payout Ratio(TTM) | -- | 43.91 | 41.03 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 4.31 | 12.75 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 4.07 | 5.84 | |
| Sales - 5 Yr. Growth Rate | -- | 10.91 | 11.23 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -- | 44.94 | 47.15 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -- | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 10.31 | 10.85 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 15.88 | 15.20 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.15 | 2.25 |
| Current Ratio (MRQ) | -- | 2.97 | 3.08 |
| LT Debt to Equity (MRQ) | -- | 8.84 | 11.38 |
| Total Debt to Equity (MRQ) | -- | 12.89 | 16.12 |
| Interest Coverage (TTM) | -- | 33.79 | 29.47 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 53.68 | 53.81 | |
| Gross Margin - 5 Yr. Avg. | -- | 51.67 | 52.18 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 17.96 | 12.87 | |
| Operating Margin (TTM) | -- | 14.31 | 6.20 | |
| Operating Margin - 5 Yr. Avg. | -- | 14.24 | 8.31 | |
| Pre-Tax Margin (TTM) | -- | 14.85 | 7.16 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 14.68 | 8.61 | |
| Net Profit Margin (TTM) | -- | 11.08 | 3.30 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 11.02 | 4.89 | |
| Effective Tax Rate (TTM) | -- | 23.02 | 22.91 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.16 | 23.38 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | -- | 957,645,487 | 842,398,385 | |
| Net Income/Employee (TTM) | -- | 113,564,537 | 99,842,801 | |
| Receivable Turnover (TTM) | -- | 5.71 | 5.71 | |
| Inventory Turnover (TTM) | -- | 2.61 | 3.47 | |
| Asset Turnover (TTM) | -- | 0.97 | 0.93 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -- | 11.52 | 11.06 | |
| Return on Assets - 5 Yr. Avg. | -- | 12.92 | 12.20 | |
| Return on Investment (TTM) | -- | 14.95 | 14.45 | |
| Return on Investment - 5 Yr. Avg. | -- | 16.84 | 15.87 | |
| Return on Equity (TTM) | -- | 16.27 | 15.96 | |
| Return on Equity - 5 Yr. Avg. | -- | 17.77 | 17.00 | |
Note: Units in Millions of US Dollars
Performance for Apellis Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -- | -- | -- | 22 |
| 13 Week | -- | -- | -- | 39 |
| 26 Week | -- | -- | -- | 33 |
| 52 Week | -- | -- | -- | 9 |
| YTD | -- | -- | -- | 26 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 59.34% |
| # of Holders: | 142 |
| Total Shares Held: | 33,375,014 |
| 3 Mo. Net Change: | 830,949 |
| # New Positions: | 33 |
| # Closed Positions: | 14 |
| # Increased Positions: | 82 |
| # Reduced Positions: | 49 |
| # Net Buyers: | 33 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.